<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913313</url>
  </required_header>
  <id_info>
    <org_study_id>CA020-002</org_study_id>
    <secondary_id>2016-002263-34</secondary_id>
    <nct_id>NCT02913313</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread</brief_title>
  <official_title>Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of experimental
      medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are
      advanced or have spread.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">December 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events of nivolumab (BMS-936558) and BMS-986207 when given in combination</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant abnormalities in general laboratory tests of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant abnormalities in general laboratory tests of nivolumab(BMS-936558) and BMS-986207 when given in combination</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median Duration of Response (mDOR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFSR)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Includes pre-dose concentrations [C0] and Ctau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(tau)] of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentration at the end of a dosing interval (Ctau) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life (T-HALFeff) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>explains degree of accumulation observed for a specific exposure measure [exposure measure includes AUC(tau)] derived from serum concentration versus time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI) of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Ratio of exposure measure at steady state to that after the first dose (exposure measure includes AUC[tau]) derived from serum concentration versus time data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration of BMS-986207 over a dosing interval</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Css-avg= AUC[TAU]/tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by the occurrence of anti-drug antibody after the administration of BMS-986207 in combination with nivolumab (BMS-936558)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokines profiling for BMS-986207</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum proteome analysis for BMS-986207</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-specific immune cells for BMS-986207</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor infiltrating lymphocyte (TIL) evaluations for BMS-986207 in combination with nivolumab (BMS-936558)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokines profiling for BMS-986207 in combination with nivolumab (BMS-936558)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum proteome analysis for BMS-986207 in combination with nivolumab(BMS-936558)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-cytometry evaluation of circulating immune cell subsets for BMS-986207 in combination with nivolumab (BMS-936558)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-specific immune cells for BMS-986207 in combination with nivolumab(BMS-936558)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This is how the pharmacodynamic activity will be measured</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Broad Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1A- Dose Escalation- Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B- Dose Escalation- Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A- Expansion- Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B- Expansion- Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986207</intervention_name>
    <arm_group_label>Part 1A- Dose Escalation- Monotherapy</arm_group_label>
    <arm_group_label>Part 1B- Dose Escalation- Combination Therapy</arm_group_label>
    <arm_group_label>Part 2A- Expansion- Monotherapy</arm_group_label>
    <arm_group_label>Part 2B- Expansion- Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Part 1B- Dose Escalation- Combination Therapy</arm_group_label>
    <arm_group_label>Part 2B- Expansion- Combination Therapy</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Women and men â‰¥18 years of age with Eastern Cooperative Oncology Group (ECOG)
             performance status of 0 or 1

          -  Must have received and progressed on or failed one standard/approved treatment for
             cancer type, if available

          -  At least 4 weeks since any previous treatment for cancer

          -  Subject must consent to pretreatment and on treatment tumor biopsies

          -  At least one lesion with measurable disease at baseline

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Patients with primary brain tumors or primary tumors with central nervous system
             metastases as only location of disease. Controlled brain metastases are permitted

          -  Prior organ transplant

          -  Participants with second/other active cancers requiring current treatment

          -  Uncontrolled/significant heart disease

          -  History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or
             Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency
             Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)

          -  Active/uncontrolled autoimmune disease

          -  Active infection

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

